This research investigates the effect of the Chaenomelis fructus(CMF) on Alzheimer's disease.
Specifically, the effects of the CMF extract on (1) IL-1β, IL-6, and TNF-α mRNA of PC-12 cells treated with LPS; (2) amyloid precursor proteins(APP), acetylcholinesterase(AChE), and glial fibrillary acidic protein(GFAP) mRNA of PC-12 cells treated with CT-105; (3) the AChE activity and the APP production of PC-12 cell treated with CT-105; (4) the behavior of AD mice with βA; (5) expression of IL-1β, TNF-α, MDA, IL-1β mRNA, TNF-α mRNA, and ROS; (6) the infarction area of the hippocampus, and brain tissue injury in Alzheimer's diseased mice induced with βA were investigated.
The results were summarized as follows ;
1. The CMF extract suppressed the expression of IL-1β, IL-6 and TNF-α mRNA in THP-1 cells treated with LPS.
2. The CMF extract suppressed the expression of APP, AChE, and GFAP mRNA in PC-12 cells treated with CT-105.
3. The CMF extract suppressed the AChE activity, and the production of APP significantly in PC-12 cells treated with CT-105.
4. A significant inhibitory effect on the memory deficit was shown on the CMF extract group of the mice with Alzheimer's disease induced by βA in the Morris water maze experiment, which measured stop-through latency, and distance movement-through latency.
5. The CMF extract suppressed the over-expression of IL-1β protein, TNF-α protein, MDA, IL-1β mRNA, TNF-α mRNA, CD68/GFAP, and ROS in the mice with Alzheimer's disease induced by βA.
6. The CMF extract reduced the infarction area of hippocampus, and controlled the injury of brain tissue in the mice with Alzheimer's disease induced by βA.
These results suggest that the CMF extract may be effective for the treatment of Alzheimer's disease. Investigation into the clinical use of the CMF extract for Alzheimer's diseaseis suggested for future research.
This research investigates the effect of the Chaenomelis fructus(CMF) on Alzheimer's disease.
Specifically, the effects of the CMF extract on (1) IL-1β, IL-6, and TNF-α mRNA of PC-12 cells treated with LPS; (2) amyloid precursor proteins(APP), acetylcholinesterase(AChE), and glial fibrillary acidic protein(GFAP) mRNA of PC-12 cells treated with CT-105; (3) the AChE activity and the APP production of PC-12 cell treated with CT-105; (4) the behavior of AD mice with βA; (5) expression of IL-1β, TNF-α, MDA, IL-1β mRNA, TNF-α mRNA, and ROS; (6) the infarction area of the hippocampus, and brain tissue injury in Alzheimer's diseased mice induced with βA were investigated.
The results were summarized as follows ;
1. The CMF extract suppressed the expression of IL-1β, IL-6 and TNF-α mRNA in THP-1 cells treated with LPS.
2. The CMF extract suppressed the expression of APP, AChE, and GFAP mRNA in PC-12 cells treated with CT-105.
3. The CMF extract suppressed the AChE activity, and the production of APP significantly in PC-12 cells treated with CT-105.
4. A significant inhibitory effect on the memory deficit was shown on the CMF extract group of the mice with Alzheimer's disease induced by βA in the Morris water maze experiment, which measured stop-through latency, and distance movement-through latency.
5. The CMF extract suppressed the over-expression of IL-1β protein, TNF-α protein, MDA, IL-1β mRNA, TNF-α mRNA, CD68/GFAP, and ROS in the mice with Alzheimer's disease induced by βA.
6. The CMF extract reduced the infarction area of hippocampus, and controlled the injury of brain tissue in the mice with Alzheimer's disease induced by βA.
These results suggest that the CMF extract may be effective for the treatment of Alzheimer's disease. Investigation into the clinical use of the CMF extract for Alzheimer's diseaseis suggested for future research.